RPRX SEC Filings: 8-K, 10-Q, S-3 & 424B – Royalty Pharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Royalty Pharma Reports Third Quarter 2026 Results and Raises Full-Year Guidance

Nov 4, 2026

8-K

Royalty Pharma Reports Second Quarter 2026 Results and Raises Full-Year Guidance

Aug 5, 2026

8-K

Royalty Pharma plc Announces Results of 2026 Annual General Meeting

Jun 4, 2026

8-K

Royalty Pharma plc Enters Into New $1.8 Billion Revolving Credit Agreement

May 28, 2026

8-K

Royalty Pharma Reports Q1 2026 Financial Results and Raises Full-Year Guidance

May 6, 2026

8-K

Royalty Pharma Triggers $250 Million Funding Milestone Following Positive Phase 3 Results for Revolution Medicines’ Daraxonrasib

Apr 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Sep 3, 2025

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Sep 2, 2025

425

Form 425 - Prospectuses and communications, business combinations

Jan 15, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jun 4, 2024

424B5

PENDING OFFERING | Bank: BofA Securities, Citigroup, J.P. Morgan, Morgan Stanley, TD Securities

Jun 3, 2024

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Nov 16, 2023

Registrations

TYPE

HEADLINE

FILED AT

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Sep 2, 2025

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Sep 2, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 16, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Jun 3, 2024

S-3ASR

SHELF

Jun 3, 2024

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Jul 15, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 11, 2025

DEFM14A

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Apr 11, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 5, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Coyne Terrance P. (Reporting)

Nov 6, 2026

Urist Marshall (Reporting)

Nov 6, 2026

Legorreta Pablo G. (Reporting)

Nov 6, 2026

Hite Christopher (Reporting)

Nov 6, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

Urist Marshall (Reporting)

Oct 5, 2026

Other

TYPE

HEADLINE

FILED AT

Royalty Pharma plc RPRX · SEC Filings